Find Clinical Trial

Open-label multicentre confirmatory study of efficacy and safety of S 95005 (TAS-102) in patients with metastatic colorectal cancer who are refractory or intolerant to standard chemotherapies


← Back
Study Phase

Phase 2

Therapeutic Area

Cancers

IndicationSolid tumors
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

TIPIRACIL, TRIFLURIDINE,
S095005

Active Substance CodeS095005
Protocol CodeCL2-95005-003
NCT CodeNCT03274882
ISRCTN CodeISRCTN14228310


Documents and links

Lay summary
Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility